A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies

NCT06718634 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Lymphoid Malignancies

Interventions

DRUG: BL-M08D1

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborators

[object Object]